Poolbeg Pharma Wins South Korean Patent for POLB 001, Kinase Inhibitor Use as Cancer CRS Prevention

MT Newswires · 3d ago
04:00 AM EDT, 10/06/2026 (MT Newswires) -- Poolbeg Pharma (POLB.L) secured a South Korean patent for the use of any p38 MAP kinase inhibitor and POLB 001 to prevent cancer immunotherapy-associated cytokine release syndrome, or CRS. The clinical-stage biopharmaceutical company said Tuesday that the patent, which will be valid until 2044, expanded its international intellectual property portfolio for its POLB 001 asset.